Rationale and supervision
This ITN proposal represents an excellent opportunity for the high-level training of Early Stage Researchers (ESRs) and Experienced Researchers (ERs) to acquire experience and skills that prepare them for leading roles in CLD research and drug discovery in European industry and academia. The different activities of the training programme, detailed below, are aimed atproviding training at three levels: 1. General expertise in the molecular mechanisms responsible for CLD and the role played by TGF-βin these processes; 2. Specific expertise in bidirectional transfer of goal-oriented scientific knowledgeand technologies between the basic, translational and clinical research and industrial capacities; 3. Complementary skills on project management, bioethics, science communication and technology transfer. The Training Programme will consist of two main modules: the Local Training Module and the Network-wide Training Module, with distinct and overlapping training nodes. These are described in greater detail below. The Network as a whole undertakes to provide 360 person-months for Early Stage Researchers whose appointment will be financed by the contract. Quantitative progress on this, in conformance with relevant contractual provisions, will be regularly monitored at consortium level.
The consortium will establish a Supervisory Board in which all Partners, one representative from the E(S)R and four external representatives will participate. The external participants are well recognized experts in their field:
Prof. Michael Trauner, MD, PhD. Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical Unversity of Vienna (Vienna, Austria).
Prof. Joan Seoane, PhD. Vall d'Hebron Institute of Oncology (Barcelona, Spain).
Prof. Carl-Henrik Heldin, MD, PhD.Ludwig Institute for Cancer Research (Uppsala, Sweden).
Prof. Michael Lahn, MD, PhD.Oncology Division, Lilly Deutschland GmbH (Bad Homberg, Germany)
We will nominate a training programme manager, that could be the coordinator of this proposal, Dr. Isabel Fabregat. Commensurate with the ITN’s ambitions, the Board will advise the network how to ensure full coverage of training in the multiple skills needed in the industry and academia to combat chronic and complex diseases such as CLD and HCC. Focus will be on enhancing E(S)R ability to assimilate the individual components of the skills spectrum needed to overseeandin a goal-oriented manner direct the multisectorial process of combatting diseases in general, but CLD in particular.